Список литературы

1. Sheth S., Bedford A., Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. American Journal of Gastroenterology 2000; 95: 1402 - 1410.

2. Hueman M.T., Vollmer C.M., Pawlik T.M. Evolving treatment strategies for gallbladder cancer. Annals of Surgical Oncology 2009; 16: 2101 - 2115.

3. Hundal R., Shaffer E.A. Gallbladder cancer: epidemiology and outcome. Clinical Epidemiology 2014; 6: 99 - 109.

4. Patel T. Cholangiocarcinoma - controversies and challenges. Nature Reviews Gastroenterology Hepatology 2011; 8: 189 - 200.

5. Yamamoto S., Kubo S., Hai S., et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Science 2004; 95: 592 - 595.

6. Welzel T.M., Graubard B.I., El-Serag H.B., et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clinical Gastroenterology Hepatology 2007; 5: 1221 - 1228.

7. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИРЦ" Минздрава России, 2019. 250 с.

8. Zhu A.X., Hong T.S., Hezel A.F., Kooby D.A. Current management of gallbladder carcinoma. Oncologist 2010; 15: 168 - 181.

9. Valle1 J. W., Borbath I., Khan S. A., et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2016; 27(suppl.5):v28-v37.Doi:10.1093/annonc/mdw324.

10. DeOliveira M.L., Cunningham S.C., Cameron J.L., et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Annals of Surgery 2007; 245: 755 - 762.

11. Lim J.H. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. American Journal of Roentgenology 2003; 181: 819 - 827.

12. Hawkins W.G., DeMatteo R.P., Jarnagin W.R., et al. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Annals of Surgical Oncology 2004; 11: 310 - 315.

13. Jarnagin W.R., Ruo L., Little S.A., et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003; 98: 1689 - 1700.

14. Furlan A., Ferris J.V., Hosseinzadeh K., Borhani A.A. Gallbladder carcinoma update: multimodality imaging evaluation, staging, and treatment options. American Journal of Roentgenology 2008; 191: 1440 - 1447.

15. Miller G., Schwartz L.H., D"Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surgical Oncology Clinics of North America 2007; 16: 343 - 368.

16. Levy A.D., Murakata L.A., Rohrmann C.A., Jr. Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics 2001; 21: 295 - 314.

17. Petrowsky H., Wildbrett P., Husarik D.B., et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. Journal of Hepatology 2006; 45(1): 43 - 50.

18. Khan Z.S., Livingston E.H., Huerta S. Reassessing the need for prophylactic surgery in patients with porcelain gallbladder: case series and systematic review of the literature. Archives of Surgery 2011; 146: 1143 - 1147.

19. Eckel F., Brunner T. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Jelic Annals of Oncology 2011; 22(suppl.6):vi40-vi44. Doi:10.1093/annonc/mdr375.

20. Zografos G., Farfaras A., Zagouri F., et al. Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreatic Diseases International 2011; 10(1): 10 - 20.

21. Nagino M., Kamiya J., Nishio H., et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Annals of Surgery 2006; 243: 364 - 372.

22. Regimbeau J.M., Fuks D., Le Treut Y.-P., et al. Surgery for Hilar Cholangiocarcinoma: A Multi-institutional Update on Practice and Outcome by the AFC-HC Study Group. Journal of Gastrointestinal Surgery 2011; 15: 480 - 488.

23. Coburn N.G., Cleary S.P., Tan J.C., Law C.H. Surgery for gallbladder cancer: a population-based analysis. Journal of the American College of Surgeons 2008; 207: 371 - 382.

24. Downing S.R., Cadogan K.A., Ortega G., et al. Early-stage gallbladder cancer in the surveillance, epidemiology, and end results database: Effect of extended surgical resection. Archives of Surgery 2011; 146: 734 - 738.

25. Goetze T.O., Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry. Annals of Surgery 2008; 247: 104 - 108.

26. Murakami Y., Uemura K., Sudo T., et al. Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma. Annals of Surgical Oncology 2011; 18: 651 - 658.

27. Meyer C.G., Penn I., James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69: 1633 - 1637.

28. Zografos G., Farfaras A., Zagouri F., et al. Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreatic Diseases International 2011; 10(1): 10 - 20.

29. Neuhaus P., Jonas S., Settmacher U., et al. Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality. Langenbeck's Archives of Surgery 2003; 388: 194 - 200.

30. Nagino M., Kamiya J., Arai T., et al. 'Anatomic' right hepatic trisectionectomy (extended right hepatectomy) with caudate lobectomy for hilar cholangiocarcinoma. Annals of Surgery 2006; 243: 28 - 32.

31. Бредер В.В., Косырев В.Ю., Ледин Е.В. Практические рекомендации по лекарственному лечению билиарного рака. RUSSCO 2017; 3(suppl.2):352-366. Doi:10.18027/2224-5057-2017-7-3s2-352-366.

32. Benson A.B., Michael I. D'Angelica M.I., Abbott D., et al. Hepatobiliary Cancers. NCCN Clinical Practice Guidelines in Oncology 2018; 1: 1 - 140.

33. Ma N., Cheng H., Qin B., et al. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer 2015; 15: 615.

34. Ben-Josef E., Guthrie K.A., El-Khoueiry A.B., et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of Clinical Oncology 2015; 33(24): 2617 - 2622.

35. Fisher S.B., Patel S.H., Kooby D.A., et al. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB (Oxford) 2012; 14: 514 - 522.

36. Hyder O., Hatzaras I., Sotiropoulos G.C., et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 2013; 153: 811 - 818.

37. Murakami Y., Uemura K., Sudo T., et al. Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma. Annals of Surgical Oncology 2011; 18: 651 - 658

38. Kelley S.T., Bloomston M., Serafini F., et al. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. The American Surgeon 2004; 70: 743 - 749.

39. Cereda S., Belli C., Reni M. Adjuvant treatment in biliary tract cancer: to treat or not to treat? World Journal of Gastroenterology 2012; 18: 2591 - 2596.

40. Mambrini A., Guglielmi A., Pacetti P., et al. Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study. Anticancer Research 2007; 27: 3009 - 3013.

41. Shitara K., Ikami I., Munakata M., et al. Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma. Clinical Oncology (R CollRadiol) 2008; 20: 241 - 246.

42. Inaba Y., Arai Y., Yamaura H., et al. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). American Journal of Clinical Oncology 2011; 34: 58 - 62.

43. Kemeny N.E., Schwartz L., Gonen M., et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology 2011; 80: 153 - 159.

44. Boehm L.M., Jayakrishnan T.T., Miura J.T., et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. Journal of Surgical Oncology 2015; 111: 213 - 220.

45. Ortner M.E., Caca K., Berr F., et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355 - 1363.

46. Zoepf T., Jakobs R., Arnold J.C., et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. American Journal of Gastroenterology 2005; 100: 2426 - 2430.

47. Ghafoori A.P., Nelson J.W., Willett C.G., et al. Radiotherapy in the Treatment of Patients with Unresectable Extrahepatic Cholangiocarcinoma. International Journal of Radiation Oncology, Biology, Physics 2011; 81(3): 654 - 659.

48. Eckel F., Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. British Journal of Cancer 2007; 96: 896 - 902.

49. Yonemoto N., Furuse J., Okusaka T., et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Japanese Journal of Clinical Oncology 2007; 37: 843 - 851.

50. Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New England Journal of Medicine 2010; 362: 1273 - 1281.

51. Lamarca A., Palmer D.H., Wasan H.S., et al. of the Advanced Biliary Cancer (ABC) Working Group.ABC-06|A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.J Clin Oncol 2019; 37(suppl.; abstr. 4003).

52. Cong W.M. Surgical pathology of hepatobiliary tumors. Springer 2017: 1 - 372.

53. Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D; ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep; 27(suppl 5):v28-v37.

54. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020 Jan 1; 38(1): 1 - 10. doi: 10.1200/JCO.19.02105.

55. Soreide K. et al. Systematic review of management of incidental gallbladder cancer after cholecystectomy //British Journal of Surgery. - 2019. - Т. 106. - N. 1. - С. 32 - 45.

56. Asher A., Ng A., Engle J. Principles of Cancer Rehabilitation //Cardio-Oncology: Principles, Prevention and Management. - Elsevier Inc., 2016. - С. 279 - 296.

57. Завражнов А.А. и др. Значение малоинвазивных методов декомпрессии желчных протоков в лечении больных с механической желтухой//Журнал им. Н.В. Склифосовского Неотложная медицинская помощь. - 2012. - N. 2.

58. Tella S. H. et al. Second-line therapies in advanced biliary tract cancers //The Lancet Oncology. - 2020. - Т. 21. - N. 1. - С. e29 - e41.

59. Dodagoudar C. et al. FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients //Japanese journal of clinical oncology. - 2016. - Т. 46. - N. 1. - С. 57 - 62.

60. Knox J. J. et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial//Journal of Clinical Oncology. - 2005. - Т. 23. - N. 10. - С. 2332 - 2338.

61. Jang J. S. et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial//Cancer chemotherapy and pharmacology. - 2010. - Т. 65. - N. 4. - С. 641 - 647.

62. Kim S. T. et al. Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial //Journal of Cancer. - 2019. - Т. 10. - N. 25. - С. 6185 - 6190.